The effect of comorbidities on glycemic control among Colombian adults with diabetes mellitus: a longitudinal approach with real-world data

dc.contributor.authorUrina-Jassir, Manuel
dc.contributor.authorHerrera-Parra, Lina Johana
dc.contributor.authorHernández Vargas, Juliana Alexandra
dc.contributor.authorValbuena-García, Ana María
dc.contributor.authorAcuña-Merchán, Lizbeth
dc.contributor.authorUrina-Triana, Miguel
dc.description.abstractBackground: Achieving an optimal glycemic control has been described to reduce the incidence of diabetes mellitus (DM) related complications. The association between comorbidities and glycemic control remains unclear. Our aim is to evaluate the effect of comorbidities on glycemic control in people living with DM. Methods: A retrospective longitudinal study on data from the National Registry of Chronic Kidney Disease from 2014 to 2019 in Colombia. The outcome was poor glycemic control (PGC = HbA1c ≥7.0%). The association between each comorbidity (hypertension (HTN), chronic kidney disease (CKD) or obesity) and PGC was evaluated through multivariate mixed effects logistic regression models. The measures of effect were odds ratios (OR) and their 95% confidence intervals (CI). We also evaluated the main associations stratified by gender, insurance, and early onset diabetes as well as statistical interaction between each comorbidity and ethnicity. Results: From 969,531 people at baseline, 85% had at least one comorbidity; they were older and mostly female. In people living with DM and CKD, the odds of having a PGC were 78% (OR: 1.78, CI 95%: 1.55-2.05) higher than those without CKD. Same pattern was observed in obese for whom the odds were 52% (OR: 1.52, CI 95%: 1.31-1.75) higher than in non-obese. Non-significant association was found between HTN and PGC. We found statistical interaction between comorbidities and ethnicity (afro descendant) as well as effect modification by health insurance and early onset DM. Conclusions: Prevalence of comorbidities was high in adults living with DM. Patients with concomitant CKD or obesity had significantly higher odds of having a PGC.eng
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.sourceBMC Endocrine Disorderseng
dc.sourceVol. 21 N° 128, (2021)
dc.subjectGlycated hemoglobin A1ceng
dc.subjectDiabetes mellituseng
dc.subjectChronic kidney Diseaseeng
dc.titleThe effect of comorbidities on glycemic control among Colombian adults with diabetes mellitus: a longitudinal approach with real-world dataeng
dc.type.spaArtículo científicospa
dcterms.referencesSaeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.eng
dcterms.referencesVargas-Uricoechea H, Casas-Figueroa LÁ. An epidemiologic analysis of diabetes in Colombia. Ann Glob Health. 2015;81:742–53.eng
dcterms.referencesHarding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62: 3–16.eng
dcterms.referencesHerman WH, Braffett BH, Kuo S, Lee JM, Brandle M, Jacobson AM, et al. What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes? J Diabetes Complicat. 2018;32:911–5.eng
dcterms.referencesZoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5:431–7.eng
dcterms.referencesRay KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–72.eng
dcterms.referencesHayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al. Followup of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197–206.eng
dcterms.referencesMannucci E, Monami M, Dicembrini I, Piselli A, Porta M. Achieving HbA1c targets in clinical trials and in the real world: a systematic review and metaanalysis. J Endocrinol Investig. 2014;37:477–95.eng
dcterms.referencesDe Pablos-Velasco P, Parhofer KG, Bradley C, Eschwège E, Gönder-Frederick L, Maheux P, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: Data from the PANORAMA study. Clin Endocrinol (Oxf). 2014;80:47–56.eng
dcterms.referencesSmalls BL, Ritchwood TD, Bishu KG, Egede LE. Racial/ethnic differences in glycemic control in older adults with type 2 diabetes: United States 2003– 2014. Int J Environ Res Public Health. 2020;17:950.eng
dcterms.referencesSuh DC, Choi IS, Plauschinat C, Kwon J, Baron M. Impact of comorbid conditions and race/ethnicity on glycemic control among the US population with type 2 diabetes, 1988-1994 to 1999-2004. J Diabetes Complicat. 2010;24:382–91.eng
dcterms.referencesChetoui A, Kaoutar K, Elmoussaoui S, Boutahar K, El Kardoudi A, Chigr F, et al. Prevalence and determinants of poor glycaemic control: a crosssectional study among Moroccan type 2 diabetes patients. Int Health. 2020; 00:1–8.eng
dcterms.referencesIglay K, Hannachi H, Howie PJ, Xu J, Li X, Engel SS, et al. Prevalence and coprevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32:1243–52.eng
dcterms.referencesLuijks H, Biermans M, Bor H, van Weel C, Lagro-Janssen T, de Grauw W, et al. The effect of comorbidity on glycemic control and systolic blood pressure in type 2 diabetes: a cohort study with 5 year follow-up in primary care. PLoS One. 2015;10:e0138662.eng
dcterms.referencesBralić Lang V, Bergman MB. Prevalence of comorbidity in primary care patients with type 2 diabetes and its association with elevated HbA1c: a cross-sectional study in Croatia. Scand J Prim Health Care. 2016;34:66–72.eng
dcterms.referencesHudon C. Comorbidity and glycemia control among patients with type 2 diabetes in primary care. Diabetes Metab Syndr Obes Targets Ther. 2008;1: 33–7.eng
dcterms.referencesAlmetwazi M, Alwhaibi M, Balkhi B, Almohaini H, Alturki H, Alhawassi T, et al. Factors associated with glycemic control in type 2 diabetic patients in Saudi Arabia. Saudi Pharm J. 2019;27:384–8.eng
dcterms.referencesAlzaheb R, Altemani A. The prevalence and determinants of poor glycemic control among adults with type 2 diabetes mellitus in Saudi Arabia. Diabetes Metab Syndr Obes Targets Ther. 2018;11:15–21.eng
dcterms.referencesMinisterio de Salud y Proteccion Social - Republica de Colombia. Resolucion 2643 del 2014; 2014. p. 1–13. uploads/2019/10/Resolucion-02463-de-2014-ERC.pdf. Accessed 9 Oct 2020eng
dcterms.referencesMinisterio de Salud y Proteccion Social - Republica de Colombia. Cifras de aseguramiento en salud con corte diciembre 2020. 2020. https://www. Accessed 19 Jan 2021.eng
dcterms.referencesMinisterio de Salud y Protección Social de Colombia. Guía de práctica clínica Hipertensión arterial primaria (HTA). 2013. co/sites/rid/Lists/BibliotecaDigital/RIDE/INEC/IETS/GPC_Completa_HTA.pdf. Accessed 22 Apr 2021.eng
dcterms.referencesMinisterio de Salud y Protección Social de Colombia. Guía de Práctica Clínica para el manejo de la hipertensión arterial primaria (HTA). 2017; 2da edición. Guía No.18. Conv_500/GPC_hta/gpc_hta_profesionales.aspx. Accessed 22 Apr
dcterms.referencesMinisterio de Salud y Protección Social de Colombia. Guía de Práctica Clínica para el diagnóstico y tratamiento de la Enfermedad Renal Crónica (adopción). 2016. conv/GPC_e_renal/gpc_e_renal_completa.aspx. Accessed 22 Apr
dcterms.referencesWHO Consultation on Obesity (1999:Geneva Switzerland) & World Health Organization. Obesity: Preventing and managing the global epidemic: Report of a WHO Consultation (WHO Technical Report Series 894). 2000:1- 252. Accessed 9 Oct 2020.eng
dcterms.referencesAmerican Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl. 1):S66–76.eng
dcterms.referencesDepartamento Administrativo Nacional de Estadistica (DANE). Cuentas departamentales, Producto Interno Bruto por departamento 2019 preliminar; 2020. p. 7–8. departamentales/B_2015/Bol_dptal_2019preliminar.pdf. Accessed 10 Nov
dcterms.referencesLevey AS, Stevens LA, Schmid CH, Zhang Y (Lucy), Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.eng
dcterms.referencesKidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.eng
dcterms.referencesYang D, Dalton JE. A unified approach to measuring the effect size between two groups using SAS®. SAS Glob Forum Stat Data Anal. 2012;335:1–6.eng
dcterms.referencesWilmot E, Idris I. Early onset type 2 diabetes: risk factors, clinical impact and management. Ther Adv Chronic Dis. 2014;5:234–44.eng
dcterms.referencesKidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98:S1–115.eng
dcterms.referencesSosa-Rubí SG, Galárraga O, López-Ridaura R. Diabetes treatment and control: the effect of public health insurance for the poor in Mexico. Bull World Health Organ. 2009;87:512–9.eng
dcterms.referencesZhang X, McKeever Bullard K, Gregg EW, Beckles GL, Williams DE, Barker LE, et al. Access to health care and control of ABCS of diabetes. Diabetes Care. 2012;35:1566–71.eng
dcterms.referencesMinisterio de Salud y Protección Social de Colombia. Todo lo que usted debe saber sobre el plan de beneficios POS. 2014. https://www.minsalud. sobre-el-plan-de-beneficios.pdf. Accessed 7 May
dcterms.referencesCopur S, Onal EM, Afsar B, Ortiz A, van Raalte DH, Cherney DZ, et al. Diabetes mellitus in chronic kidney disease: biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality. J Diabetes Complicat. 2020;34:107707.eng
dcterms.referencesDe Cosmo S, Viazzi F, Pacilli A, Giorda C, Ceriello A, Gentile S, et al. Achievement of therapeutic targets in patients with diabetes and chronic kidney disease: insights from the Associazione Medici Diabetologi annals initiative. Nephrol Dial Transplant. 2015;30:1526–33.eng
dcterms.referencesBae JP, Lage MJ, Mo D, Nelson DR, Hoogwerf BJ. Obesity and glycemic control in patients with diabetes mellitus: analysis of physician electronic health records in the US from 2009-2011. J Diabetes Complicat. 2016;30: 212–20.eng
dcterms.referencesSpeeckaert M, Van Biesen W, Delanghe J, Slingerland R, Wiecek A, Heaf J, et al. Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population? Nephrol Dial Transplant. 2014;29:2167–77.eng
dcterms.referencesHill CJ, Maxwell AP, Cardwell CR, Freedman BI, Tonelli M, Emoto M, et al. Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: a meta-analysis. Am J Kidney Dis. 2014;63:84–94.eng
dcterms.referencesKuo I-C, Lin HY-H, Niu S-W, Hwang D-Y, Lee J-J, Tsai J-C, et al. Glycated hemoglobin and outcomes in patients with advanced diabetic chronic kidney Disease. Sci Rep. 2016;6:20028.eng
dcterms.referencesEsteghamati A, Ismail-Beigi F, Khaloo P, Moosaie F, Alemi H, Mansournia MA, et al. Determinants of glycemic control: phase 2 analysis from nationwide diabetes report of National Program for prevention and control of diabetes (NPPCD-2018). Prim Care Diabetes. 2020;14:222–31.eng
dcterms.referencesGummesson A, Nyman E, Knutsson M, Karpefors M. Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19:1295–305.eng
dcterms.referencesLerman-Garber I, Aguilar-Salinas C, Tusié-Luna T, Velásquez D, Lobato- Valverde M, Osornio-Flores M, et al. Diabetes tipo 2 de inicio temprano. Experiencia en una institución de tercer nivel de atención médica. Gac Med Mex. 2010;146:179–
dcterms.referencesBo A, Thomsen RW, Nielsen JS, Nicolaisen SK, Beck-Nielsen H, Rungby J, et al. Early-onset type 2 diabetes: age gradient in clinical and behavioural risk factors in 5115 persons with newly diagnosed type 2 diabetes-results from the DD2 study. Diabetes Metab Res Rev. 2018;34:e2968.eng
dcterms.referencesGopalan A, Mishra P, Alexeeff SE, Blatchins MA, Kim E, Man A, et al. Initial glycemic control and care among younger adults diagnosed with type 2 diabetes. Diabetes Care. 2020;43:975–81.eng
dcterms.referencesBadedi M, Solan Y, Darraj H, Sabai A, Mahfouz M, Alamodi S, et al. Factors associated with long-term control of type 2 diabetes mellitus. J Diabetes Res. 2016;2016:2109542.eng
dcterms.referencesMenzin J, Korn JR, Cohen J, Lobo F, Zhang B, Friedman M, et al. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. J Manag Care Pharm. 2010;16:264–75.eng
dcterms.referencesGil J, Sicras-Mainar A, Zucchelli E. Uncontrolled diabetes and health care utilisation: panel data evidence from Spain. Eur J Health Econ. 2018;19:785–95.eng
dcterms.referencesMata-Cases M, Rodríguez-Sánchez B, Mauricio D, Real J, Vlacho B, Franch- Nadal J, et al. The association between poor glycemic control and health care costs in people with diabetes: a population-based study. Diabetes Care. 2020;43:751–8.eng


Bloque original
Mostrando 1 - 1 de 1
The effect of comorbidities on glycemic.pdf
901.5 KB
Adobe Portable Document Format
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
381 B
Item-specific license agreed upon to submission